Prelude Therapeutics Inc — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Prelude Therapeutics reported Q3 2026 results with $142.7M in cash/equivalents/securities as of September 30, 2026, funding operations into Q2 2028. The company initiated Phase 1 enrollment of PRT13722 (KAT6A degrader) in HR+ breast cancer in Q4 2026 with initial proof-of-concept data expected H2 2027; in October 2026 entered a clinical trial collaboration and supply agreement with Eli Lilly to evaluate PRT13722 in combination with abemaciclib (Verzenio) and imlunestrant (Inluriyo). PRT12396 (JAK2V617F mutant-selective inhibitor) Phase 1 enrollment ongoing in MF/PV; subject to exclusive option agreement with Incyte expiring February 2027 (with potential 3-month extension). mCALR-targeted degrader antibody conjugate program advancing to development candidate nomination by year-end 2026. Net loss for Q3 2026 was $12.5M ($0.12/share) on 103.1M weighted-average shares, improved from $19.7M ($0.26/share) in Q3 2025.
Why this rating
Early-stage biotech with modest cash cushion and multiple Phase 1 programs; Lilly collaboration and clinical progress are meaningful but company size (~$14.4M market cap) limits event magnitude relative to business trajectory.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.